Horizon scanning for novel therapeutics for the treatment of prostate cancer
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Horizon scanning for novel therapeutics for the treatment of prostate cancer
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 21, Issue Supplement 7, Pages vii43-vii55
Publisher
Oxford University Press (OUP)
Online
2010-10-19
DOI
10.1093/annonc/mdq369
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015
- (2016) Robert Bok Therapeutics and Clinical Risk Management
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
- (2009) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study
- (2009) Primo N. Lara et al. ANTI-CANCER DRUGS
- Novel Agents on the Horizon for Cancer Therapy
- (2009) W. W. Ma et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Development of Androgen Receptor Antagonists with Promising Activity in Castration-Resistant Prostate Cancer
- (2009) Howard C. Shen et al. CANCER CELL
- Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven
- (2009) G. Attard et al. CANCER RESEARCH
- Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
- (2009) L. Gan et al. CANCER RESEARCH
- Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
- (2009) D. S. Welsbie et al. CANCER RESEARCH
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2009) E. Y. Yu et al. CLINICAL CANCER RESEARCH
- An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
- (2009) G. Liu et al. CLINICAL CANCER RESEARCH
- Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
- (2009) D. Sarker et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
- (2009) Kim N. Chi et al. EUROPEAN UROLOGY
- Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
- (2009) Quincy Siu-Chung Chu EXPERT OPINION ON BIOLOGICAL THERAPY
- New approved dasatinib regimen available for clinical use
- (2009) David S Snyder Expert Review of Anticancer Therapy
- Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells
- (2009) Federica Rizzi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
- (2009) Yu Chen et al. LANCET ONCOLOGY
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
- (2009) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions
- (2009) A Gualberto et al. ONCOGENE
- Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
- (2008) D. Olmos et al. ANNALS OF ONCOLOGY
- The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer
- (2008) Stephen J. Assinder et al. BIOCHEMICAL JOURNAL
- Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
- (2008) G Attard et al. BRITISH JOURNAL OF CANCER
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
- (2008) Jennifer S. Carew et al. CANCER LETTERS
- Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation
- (2008) X. Wang et al. CANCER RESEARCH
- Microtubule Active Agents: Beyond the Taxane Frontier
- (2008) P. G. Morris et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
- (2008) E. I. Heath et al. CLINICAL CANCER RESEARCH
- Heat Shock Protein 90 as a Drug Target: Some Like It Hot
- (2008) U. Banerji CLINICAL CANCER RESEARCH
- Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
- (2008) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
- (2008) Nicholas D. James et al. EUROPEAN UROLOGY
- Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer
- (2008) Mari Björkman et al. INTERNATIONAL JOURNAL OF CANCER
- Clusterin is epigenetically regulated in prostate cancer
- (2008) Hanna E. Rauhala et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development
- (2008) G Attard et al. JOURNAL OF CLINICAL PATHOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now